U.S. Markets open in 1 hr 56 mins

Wired News – Aimmune Therapeutics’ Peanut Allergy Drug AR101 Met Primary Endpoint in Pivotal Phase-3 Clinical Trial

Stock Monitor: Cyanotech Post Earnings Reporting

LONDON, UK / ACCESSWIRE / February 22, 2018 / Active-Investors.com has just released a free research report on Aimmune Therapeutics, Inc. (NASDAQ: AIMT). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=AIMT as the Company's latest news hit the wire. On February 20, 2018, the California-based biopharmaceutical Company announced that its pivotal Phase-3 clinical trial, PALISADE (Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults), evaluating its lead candidate AR101 for treating severe peanut allergy has met the primary endpoint. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Cyanotech Corporation (NASDAQ: CYAN), which also belongs to the Healthcare sector as the Company Aimmune Therapeutics. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=CYAN

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Aimmune Therapeutics most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=AIMT

PALISADE Trial

PALISADE was an international randomized 3:1, double-blind, placebo-controlled, Phase-3 trial of the efficacy and safety of AR101 in a Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach in patients with peanut allergy. In the study, 496 highly allergic patients of the ages 4–17 received the treatment. PALISADE enrolled peanut-allergic patients ages at more than 60 clinical sites in the United States, Canada, and eight countries in the European Union.

Results of the Trial

After one year of treatment, 76.6% of participants treated with AR101 tolerated 300 mg of peanut protein compared to 8.1% for placebo, in the exit double-blind, placebo-controlled food challenge (DBPCFC). Around 67.2% of patients tolerated at least a 600-mg dose of peanut protein compared to 4% of placebo patients. Additionally, 50.3% of AR101 patients tolerated a single highest dose of 1,000 mg of peanut protein compared to 2.4% of placebo patients. The participants could tolerate no more than 30 mg of peanut protein at study entry. The pre-specified success criterion was 15%. Aimmune cleared this statistical requirement with a 53% difference. Incidences of serious adverse events (SAEs) were low. A total of 10 patients experienced SAEs, none of which were considered life-threatening. Nine of these patients were in the AR101 arm. Of the nine AR101 patients who experienced a SAE, five patients experienced mild or moderate SAEs, and the other four experienced severe SAEs.

Aimmune Plans to Seek Approval in United States and Europe for AR101

Based on the results, Aimmune expects to submit a Biologics License Application (BLA) for AR101 with the FDA by the end of 2018, followed by a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) in the first half of 2019. In the United States, AR101 has FDA Fast Track Designation as well as FDA Breakthrough Therapy Designation for peanut-allergic patients ages 4–17.

PALISADE is the Largest Peanut Allergy Trial Ever Conducted

Daniel C. Adelman, M.D., Chief Medical Officer of Aimmune, mentioned that PALISADE is not only the largest peanut allergy trial ever conducted, it is also the first to use an independent blinded assessor, and the first to accept peanut-allergic patients with a history of severe or life-threatening reactions.

Daniel added that given how robust the PALISADE results are and that they met or exceeded the pre-specified metrics, the Company is encouraged that the data from PALISADE are helping to define the magnitude of the potential treatment effect in very sensitive peanut-allergic patients.

About Peanut Allergy

Peanut allergy is a type of food allergy to peanuts. It is different from tree nut allergies. Physical symptoms of allergic reaction can include itchiness, urticaria, swelling, eczema, sneezing, asthma, abdominal pain, drop in blood pressure, diarrhea, and cardiac arrest. Anaphylaxis may occur. It is due to a type-I hypersensitivity reaction of the immune system in susceptible individuals. The allergy is recognized as one of the most severe food allergies due to its prevalence, persistency, and potential severity of allergic reaction. Currently, there is no cure for peanut allergy.

About AR101

AR101, Aimmune's lead investigational drug, is an investigational oral biologic drug designed to help protect patients from severe allergic reactions in case they are accidentally exposed to peanut. AR101, upon regulatory approval, would meet the stringent manufacturing and quality requirements established by regulatory authorities.

About Aimmune Therapeutics, Inc.

Founded in 2011, Aimmune Therapeutics is a clinical-stage biopharmaceutical company developing desensitization treatments to protect people with food allergies from the life-threatening consequences of accidental exposures to their allergens. The Company is headquartered in Brisbane, California.

Stock Performance Snapshot

February 21, 2018 - At Wednesday's closing bell, Aimmune Therapeutics' stock fell 7.87%, ending the trading session at $32.21.

Volume traded for the day: 2.46 million shares, which was above the 3-month average volume of 484.77 thousand shares.

Stock performance in the previous six-month period – up 67.32%; and past twelve-month period – up 60.49%

After yesterday's close, Aimmune Therapeutics' market cap was at $1.68 billion.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com
Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors